The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).

Irem Bilgetekin,Mehmet Dogan,Cengiz Karacin,Fatma Buğdaycı Başal,Ece Esin,Gökhan Uçar,Ozlem Aydin Isak,Goksen Inanc Imamoglu,Gul Sema Yildiran Keskin,Ismail Erturk,Burak Yasin Aktaş,Naziyet Kose Baytemur,Kübra Aydin,Selcuk Cemil Ozturk,Bülent Aksel,Nuri Karadurmuş,Olcay Kandemir,Berna Oksuzoglu,Umut Demirci

The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).

2021

Irem Bilgetekin
Mehmet Dogan
Cengiz Karacin
Fatma Buğdaycı Başal
Ece Esin
Gökhan Uçar
Ozlem Aydin Isak
Goksen Inanc Imamoglu
Gul Sema Yildiran Keskin
Ismail Erturk
Burak Yasin Aktaş
Naziyet Kose Baytemur
Kübra Aydin
Selcuk Cemil Ozturk
Bülent Aksel
Nuri Karadurmuş
Olcay Kandemir
Berna Oksuzoglu
Umut Demirci

e15587Background: Expanded RAS analysis is essential for the selection of biologic agents in mCRC. RAS mutations indicates anti-EGFR unresponsiveness. In this study, we aimed to investigate RAS and...

Keywords:

Medicine
Internal medicine
Oncology
in patient
Selection (genetic algorithm)
Colorectal cancer
Bevacizumab
Biologic Agents
Mutation (genetic algorithm)
Liquid biopsy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations